Bladder carcinoma in situ

Summary

Bladder carcinoma in situ (MONDO:0004703) is a cancer and 24 clinical trials. Top therapeutic interventions include mitomycin, talimogene laherparepvec, and programmed cell death 1 ligand 1. A subtype of non-invasive bladder urothelial carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 24

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bladder carcinoma in situ
Mondo ID	MONDO:0004703
DOID	DOID:9053
ICD-10-CM	D09.0
NCIT	C3644
SNOMED CT	92546004
UMLS	C0154091
MedGen	57584
GARD	0024091
Anatomy (UBERON)	UBERON:0001255
Is cancer (heuristic)	yes

Also known as: bladder flat carcinoma in situ · bladder flat CIS · cancer in situ of urinary bladder · carcinoma in situ of bladder · carcinoma in situ of the urinary bladder · carcinoma in situ of urinary bladder · flat carcinoma in situ of the bladder · flat carcinoma in situ of the urinary bladder · flat CIS of the bladder · flat CIS of the urinary bladder · high grade bladder Intraurothelial neoplasia · stage 0 urinary bladder carcinoma · stage 0is bladder cancer · stage 0is bladder carcinoma · stage 0is bladder urothelial cancer · stage 0is bladder urothelial carcinoma · stage 0is bladder urothelial carcinoma aJCC v6 · stage 0is bladder urothelial carcinoma aJCC v6 and v7 · stage 0is bladder urothelial carcinoma aJCC v7 · stage 0is carcinoma of bladder (+8 more)

Disease family

This is a subtype of non-invasive bladder urothelial carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › urinary bladder neoplasm › urinary bladder cancer › urinary bladder carcinoma › bladder transitional cell carcinoma › non-invasive bladder urothelial carcinoma › bladder carcinoma in situ

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 24.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	7
Not specified	7
PHASE2	6
PHASE3	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03091660	PHASE3	ACTIVE_NOT_RECRUITING	S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
NCT05024773	PHASE3	RECRUITING	Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
NCT03335059	PHASE3	TERMINATED	Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.
NCT04164082	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
NCT06704191	PHASE1/PHASE2	RECRUITING	In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
NCT07189793	PHASE2	NOT_YET_RECRUITING	Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study
NCT00749892	PHASE2	COMPLETED	Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
NCT02844816	PHASE2	COMPLETED	Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
NCT02901548	PHASE2	TERMINATED	Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
NCT04496219	PHASE2	COMPLETED	Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer
NCT05843448	PHASE1	RECRUITING	IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
NCT06173349	PHASE1	RECRUITING	PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
NCT02808143	PHASE1	COMPLETED	Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
NCT03430687	PHASE1	WITHDRAWN	Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma
NCT04548193	PHASE1	COMPLETED	Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship
NCT04798703	PHASE1	COMPLETED	Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)
NCT05375903	PHASE1	COMPLETED	A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
NCT06350734	Not specified	ACTIVE_NOT_RECRUITING	Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
NCT07231809	Not specified	NOT_YET_RECRUITING	Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients
NCT07302230	Not specified	RECRUITING	Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial
NCT01304173	Not specified	COMPLETED	Retrospective Chart Review of Valstar
NCT02494635	Not specified	TERMINATED	Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of Patients With Bladder Cancer
NCT02699853	Not specified	TERMINATED	Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer
NCT04501913	Not specified	COMPLETED	Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MITOMYCIN	4	3
TALIMOGENE LAHERPAREPVEC	4	1
PROGRAMMED CELL DEATH 1 LIGAND 1	2	1
ZALIFRELIMAB	2	1